Cantor Fitzgerald Upgrades Aclaris Therapeutics (NASDAQ:ACRS) to Strong-Buy

Aclaris Therapeutics (NASDAQ:ACRS) was upgraded by investment analysts at Cantor Fitzgerald to a “strong-buy” rating in a research note issued on Tuesday,Zacks.com reports.

Several other brokerages have also recently issued reports on ACRS. Leerink Partnrs raised shares of Aclaris Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, November 19th. Leerink Partners upgraded shares of Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and lifted their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Piper Sandler upgraded shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their price target for the stock from $3.00 to $13.00 in a research note on Monday, November 18th. StockNews.com lowered shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 8th. Finally, BTIG Research upgraded shares of Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $8.00 price target for the company in a research note on Tuesday, November 19th. One equities research analyst has rated the stock with a sell rating, five have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $11.00.

Aclaris Therapeutics Stock Performance

Shares of Aclaris Therapeutics stock opened at $1.85 on Tuesday. The stock has a market capitalization of $132.15 million, a PE ratio of -3.56 and a beta of 0.50. Aclaris Therapeutics has a 52-week low of $0.95 and a 52-week high of $5.17. The company has a 50-day simple moving average of $2.38 and a two-hundred day simple moving average of $2.18.

Institutional Trading of Aclaris Therapeutics

Several large investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP purchased a new position in shares of Aclaris Therapeutics in the fourth quarter worth $26,000. Invesco Ltd. bought a new position in Aclaris Therapeutics during the 4th quarter worth about $28,000. Graham Capital Management L.P. purchased a new position in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $35,000. Commonwealth Equity Services LLC purchased a new position in shares of Aclaris Therapeutics in the 4th quarter valued at approximately $36,000. Finally, Alpine Global Management LLC purchased a new position in Aclaris Therapeutics during the 4th quarter worth approximately $38,000. 98.34% of the stock is currently owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.